Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging
about
Nanotechnology: Future of OncotherapySonoporation enhances liposome accumulation and penetration in tumors with low EPR.Preparation and Characterization of Novel Perfluorooctyl Bromide Nanoparticle as Ultrasound Contrast Agent via Layer-by-Layer Self-Assembly for Folate-Receptor-Mediated Tumor ImagingAbsorption reconstruction improves biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography.Imalytics Preclinical: Interactive Analysis of Biomedical Volume DataTargeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles.An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors.Fluorescent nanoparticles for the accurate detection of drug delivery.GPU-Accelerated Adjoint Algorithmic DifferentiationNoninvasive Assessment of Elimination and Retention using CT-FMT and Kinetic Whole-body Modeling.Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors.Sensitivity and accuracy of hybrid fluorescence-mediated tomography in deep tissue regions.Hybrid µCT-FMT imaging and image analysis.Rethinking cancer nanotheranostics.Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.Progress and challenges towards targeted delivery of cancer therapeutics.Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft modelsPLGA-Based Nanoparticles in Cancer Treatment
P2860
Q26801067-1E61ED5F-C601-4908-90CA-2144C94DDD8FQ30358121-BD180592-366C-4C0A-B8B1-5F043340382EQ30374207-0C687BF6-D13E-43B4-BD24-D19ED8F748FDQ30432543-18B8DB40-038A-41AD-9DD2-6A6880F5516EQ31048680-690D5E67-256C-46E3-968E-39D093A1AC3CQ35787096-38C0BB6B-8DBE-4012-9814-8B568CEBE25DQ35911710-0E333DDC-445F-4A3C-91DE-6DD98D3C9584Q36596242-0F696CB2-CEB4-4309-9E4F-DD78E39FC6B3Q38570366-DAF4EFAF-EDB7-4DCF-9CA5-11B4CFAF7647Q38688745-D11B8D2D-A88A-4AF4-A361-97EBFB553BB7Q38772061-27D30482-B5F3-477B-B956-F2E9D0811DECQ38981743-6B20C680-ED07-47B3-82E2-3990FE2DBBC5Q39169488-3EBC741A-E0E9-4657-AA28-BEC346FA9027Q40845003-EA3D5004-4AC0-4C78-A7DD-8FD3AD115B69Q42640884-893B0542-14C3-48E2-AC8F-B872E5AC5D74Q42708321-E99050A6-0E51-4C67-8FD0-A55820FE9566Q52590993-FF6F2846-B45E-4639-A448-178FFA100045Q57181925-3AE7DC55-36AD-4C8B-BDAE-AA242E38AFD0Q59137460-4217E0F0-1619-4452-86D5-D098EAE561B2
P2860
Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@ast
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@en
type
label
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@ast
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@en
prefLabel
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@ast
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@en
P2093
P2860
P50
P1476
Characterizing EPR-mediated pa ...... functional ultrasound imaging
@en
P2093
Benjamin Theek
Fabian Kiessling
Felix Gremse
Gert Storm
Josef Ehling
Michal Pechar
Stanley Fokong
P2860
P356
10.1016/J.JCONREL.2014.03.007
P407
P577
2014-03-12T00:00:00Z